ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- US stock futures mixed as Apple slides, midterms loom
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IBRX Hot Sheet
Join SI Premium – FREE
ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $2.93 million.
For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xometry, Inc. (XMTR) Tops Q3 EPS by 9c ; Offers Guidance
- AdaptHealth Corp. (AHCO) Misses Q3 EPS by 120c ; Offers Guidance
- Upstart Holdings (UPST) Tops Q3 EPS by 12c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
